Merck & Co Inc
MRK: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$432.00 | Pslv | Fmsclmnr |
Merck Earnings: Strong Results Led by Keytruda and Gardasil as Pipeline Makes Strides
Merck reported strong second-quarter results slightly above our expectations and raised full-year 2023 guidance, but we don’t expect any major changes to Merck’s fair value estimate based on the minor outperformance.